Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
41 stopped studies mapped to Peripheral T-Cell Lymphoma, Not Otherwise Specified and descendants · 88% state a reason
Over the 41 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | Phase 2 | withdrawn | Nov 18, 2024 | Eric Jacobsen, MD | Ipsen requested a temporary closure due to a safety concern. | Safety / toxicity |
| NCT03590574 | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1… | Phase 1 / Phase 2 | terminated | Jul 18, 2018 | Autolus Limited | Only Phase I of the study was conducted. | Other (stated, no rule matched) |
| NCT04425070 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy…(TOUCH) | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Antengene Corporation | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT05083208 | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of… | Phase 1 | terminated | Oct 19, 2021 | Henan Cancer Hospital | The clinical development of parsaclisib was stopped by it's manufacturer. | Drug supply |
| NCT05883449 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL(LuminICE-203) | Phase 2 | terminated | Jun 1, 2023 | Affimed GmbH | Due to sponsor decision | Sponsor / business decision |
| NCT06941688 | Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for… | Phase 2 | terminated | Apr 24, 2025 | Seoul National University Hospital | slow recruitment | Enrollment / accrual |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | Phase 1 / Phase 2 | terminated | Nov 3, 2021 | National Health Research Institutes, Taiwan | The resolution of DSMB | Other (stated, no rule matched) |
| NCT04548700 | Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and… | Phase 1 | terminated | Sep 14, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT03947255 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma… | Phase 2 | terminated | May 13, 2019 | Seagen Inc. | Study stopped early due to low patient accrual. | Enrollment / accrual |
| NCT04795869 | Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral… | Phase 2 | withdrawn | Mar 12, 2021 | Northwestern University | Study inactivated due to zero accruals | Enrollment / accrual |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory… | Phase 2 / Phase 3 | withdrawn | Jul 16, 2019 | Portola Pharmaceuticals | Sponsor decision to not initiate the trial | Sponsor / business decision |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges | Enrollment / accrual |
| NCT04444141 | A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell… | Phase 1 / Phase 2 | terminated | Jun 23, 2020 | Akeso | Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop… | Sponsor / business decision |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front… | Phase 2 | withdrawn | Feb 15, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT01420679 | Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral… | Phase 3 | terminated | Aug 22, 2011 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | Phase 1 | terminated | Jul 19, 2012 | Aptevo Therapeutics | Business decision | Sponsor / business decision |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | Phase 1 / Phase 2 | withdrawn | Jun 12, 2018 | Conjupro Biotherapeutics, Inc. | IND Inactive Status | Other (stated, no rule matched) |
| NCT00632827 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using… | Phase 2 | terminated | Mar 11, 2008 | University of California, San Francisco | Manufacturing shortage of both Diftitox and Doxil | Drug supply |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT01841021 | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma… | N/A | terminated | Apr 26, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual, loss of sponsor support | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous…(PXD101-CLN-6) | Phase 2 | terminated | Jan 11, 2006 | Valerio Therapeutics | Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient… | Enrollment / accrual |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With… | N/A | withdrawn | Jan 17, 2013 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01355783 | A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the… | Phase 3 | withdrawn | May 18, 2011 | Eisai Inc. | not stated | Not stated |
| NCT01036399 | Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell… | Phase 2 | terminated | Dec 21, 2009 | University of Bologna | The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and… | Other (stated, no rule matched) |
| NCT00704691 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell… | Early Phase 1 | terminated | Jun 25, 2008 | University of Alabama at Birmingham | Closed due to futility with only 1 patient accrued | Efficacy / futility |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin… | Phase 1 | terminated | May 4, 2010 | City of Hope Medical Center | Sponsor withdrew support for the study | Other (stated, no rule matched) |
| NCT00441025 | The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed… | Phase 2 | terminated | Feb 27, 2007 | Mahidol University | a lack of a potential patient. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 21, 2026source: clinicaltrials